NEW YORK (GenomeWeb News) – Enzo Biochem has filed a shelf registration to separately offer up to $50 million of its securities and another $18 million of its common stock.

Enzo filed two prospectuses in a Form S-3 with the US Securities and Exchange Commission on Thursday. In one, the New York-based life science reagents and diagnostic testing firm said it may offer from time to time its common stock, preferred stock, depositary shares, debt securities, warrants, and units totaling no more than $50 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.

Vivek Murthy is no longer the surgeon general of the US, the Associated Press reports.

People around the globe took to the streets to support science — some with signs.